Evercore ISI Group Maintains Outperform on AbbVie, Raises Price Target to $236

Benzinga Newsdesk www.benzinga.com Positive 91.8%

Neg 0% Neu 0% Pos 91.8%

Evercore ISI Group analyst Gavin Clark-Gartner maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $232 to $236.